US 11111309
Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4
granted A61KA61K2039/505A61K47/6807
Quick answer
US patent 11111309 (Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4) held by Dyne Therapeutics, Inc. expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Dyne Therapeutics, Inc.
- Grant date
- Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K47/6807, A61K47/6849, A61K47/6889